We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ortec Announces Formation of Stem Cell and Regenerative Medicine Scientific Advisory Board

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Ortec Announces Formation of Stem Cell and Regenerative Medicine Scientific Advisory Board "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Ortec International, Inc. has announced the formation of its Stem Cell and
Regenerative Medicine Scientific Advisory Board, focused on advancing the clinical development of the Company's newly acquired proprietary fibrin derived advanced biomaterial technologies: Fibrin Micro Beads (FMB's) and Fibrin based peptides, (Haptides™).

FMB's have demonstrated the ability to efficiently recover adult stem cells from mixed cell populations as well as allow for their growth, proliferation and potential reimplantation into the patient, and Haptides™ have demonstrated the ability to enhance cell attraction and attachment allowing for the potential development of products for tissue regeneration and cosmetic tissue augmentation.

Daniel R. Marshak, Ph.D., accomplished in the field of stem cell biology and human cell research, has been appointed as the Board's Chairman. Over the coming months, Ortec expects to expand the Board.

Commenting on the appointment, Ron Lipstein, Vice Chairman and CEO of Ortec, stated, "We are quite fortunate that Dr. Marshak has agreed to chair our stem cell and regenerative medicine Scientific Advisory Board."

"We look forward to Dr. Marshak's guidance in charting the development and commercialization pathway for our newly acquired advanced biomaterials and in generating products that can make a significant contribution to stem cell therapy and regenerative medicine."

Dr. Marshak added, "I am excited to help build Ortec International's Stem Cell and Regenerative Medicine Advisory Board, which will play a guiding and directing role in the clinical development of novel technology in biomaterials and stem cells."

From 1994 through 2000, Dr. Marshak was Senior Vice President and Chief Scientific Officer for Osiris Therapeutics, Inc.

From 1986-1995, he was Senior Staff Investigator at the Cold Spring Harbor Laboratory in Long Island, New York, where he and the members of his laboratory conducted research in signal transduction, cellular growth control and differentiation.

Concurrent with that appointment, he was Assistant Professor, School of MedicineState University of New York at Stony Brook, where he taught graduate biochemistry.

Dr. Marshak currently serves as Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation, where he coordinates technology licensing and corporate collaborations in the biosciences, and participates in strategic planning for the corporation.

Dr. Marshak joined Cambrex in 2000, and through 2001, led R&D worldwide for the Bioscience sector.

Concurrent with his position at Cambrex, Dr. Marshak also holds an appointment as Adjunct Associate Professor at the Johns Hopkins University School of Medicine in Baltimore, Maryland.

Dr. Marshak has extensive research experience in the growth control of human cells. He has authored 100 scientific publications, including one textbook, and he has been editor of five monographs.

The most recent monograph, Stem Cell Biology, was published in 2001 by The Cold Spring Harbor Laboratory Press. Dr. Marshak is a graduate of Harvard University where he earned a B.A. in Biochemistry & Molecular Biology.

He earned his Ph.D. from The Rockefeller University in Biochemistry and Cell Biology and conducted postdoctoral research in Pharmacology at Vanderbilt University School of Medicine and at the National Institutes of Health.

Dr. Marshak has received several awards for scientific and academic achievements, and is an inventor on five issued U.S. patents.